• Users Online: 519
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2022  |  Volume : 12  |  Issue : 1  |  Page : 4-15

Pharmacological management of COVID-19 in pregnancy

1 Internal Medicine Department, Shiraz University of Medical Sciences, Shiraz, Iran
2 Maternal, Fetal, and Neonatal Research Center, Tehran University of Medical Sciences, Tehran, Iran
3 Maternal, Fetal, and Neonatal Research Center, Tehran University of Medical Sciences; Maternal Health Department, Iran Ministry of Health and Medical Education, Tehran, Iran
4 Breastfeeding Research Center, Tehran University of Medical Sciences, Tehran, Iran

Correspondence Address:
Nasrin Changizi
Maternal Fetal and Neonatal Research Center, Vali-Asr Hospital, Imam Khomeini Hospital Complex, Bagher Khan Ave., Tehran 1419733141
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/aihb.aihb_86_21

Rights and Permissions

Coronavirus disease 2019 (COVID-19) as a severe and rapid spread disease is a global health emergency since December 2019. During the outbreak of COVID-19, infected pregnant women were treated with different pharmacological regimens; however, trial studies are still investigating their safety and effectiveness. In the present study, we reviewed all recently published studies related to the pharmaceutical management of COVID-19 in pregnancy to discuss the rapid evolving pattern of administered medications. A review study was conducted to investigate the pharmacological management of COVID-19 in pregnancy. All types of full English and recent articles through detailed research on Cochrane Library, PubMed, UpToDate, ScienceDirect and Google Scholar databases were collected. Several medical sites were also investigated. The implemented keywords for the search were COVID-19, SARS-CoV-2, coronavirus, pregnancy, management, treatment, medication, drug, antiviral, teratogenicity, possible effect, therapeutic effect, adverse effect and pregnancy outcome. There are no definitely specific approved pharmacological treatments for COVID-19 in pregnancy. Evaluating published literature showed that different treatment options, including chloroquine, favipiravir and ribavirin, convalescent plasma, interferons and remdesivir, have been used to stop or decline viral replication. We reviewed published evidence for drug selection and its safety during pregnancy, but conflicting results associated with numbers of trials show that we need further investigation for newer antiviral drugs for use in pregnancy. It seems that management of COVID-19 needs a multidisciplinary approach, and a consultant medical team should be arranged to decide about medications for the management of COVID-19-infected pregnant women.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded19    
    Comments [Add]    

Recommend this journal